| __timestamp | Apellis Pharmaceuticals, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 60716000 |
| Thursday, January 1, 2015 | 6356782 | 119401000 |
| Friday, January 1, 2016 | 4303743 | 140879000 |
| Sunday, January 1, 2017 | 10463151 | 199243000 |
| Monday, January 1, 2018 | 22639184 | 240636000 |
| Tuesday, January 1, 2019 | 67046483 | 264359000 |
| Wednesday, January 1, 2020 | 139401000 | 260583000 |
| Friday, January 1, 2021 | 176771000 | 324951000 |
| Saturday, January 1, 2022 | 277163000 | 372766000 |
| Sunday, January 1, 2023 | 500815000 | 378378000 |
| Monday, January 1, 2024 | 396826000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, operational efficiency is key to sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Bio-Techne Corporation and Apellis Pharmaceuticals, Inc., from 2014 to 2023. Over this period, Bio-Techne consistently maintained higher SG&A expenses, peaking at approximately $397 million in 2023, reflecting a steady growth trajectory. In contrast, Apellis Pharmaceuticals exhibited a more volatile pattern, with a dramatic increase of over 17,000% from 2014 to 2023, reaching around $501 million. This surge underscores Apellis's aggressive expansion strategy. Notably, 2024 data for Apellis is missing, indicating potential reporting delays or strategic shifts. Such insights are crucial for investors and stakeholders aiming to understand the financial health and strategic priorities of these biotech giants.
Novartis AG or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and Apellis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE
Who Optimizes SG&A Costs Better? Alkermes plc or Apellis Pharmaceuticals, Inc.